2 stars Innov'Space award-winner
First intranasal vaccin against bovine respiratory coronavirus
In addition to its existing BOVILIS range, MSD Animal Health has launched BOVILIS® Nasalgen®-C, the first intranasal vaccine against bovine respiratory coronavirus (BCoV).1 This live attenuated monovalent vaccine can be administered from birth. This innovation addresses a previously orphaned pathology.
The onset of immunity is rapid and early (5 days) after the application of the intranasal dose. The product can be administered from birth (2 ml in one nostril) with or without a cannula, and is available in single doses (5x1 dose), in 5 doses, and in 20 doses. BOVILIS® Nasalgen®-C can be stored for 24 months before opening and is usable up to 24 hours after reconstitution.1
BOVILIS® Nasalgen®-C and BOVILIS® INtranasal RSP® Live - an intranasal vaccine against bovine respiratory syncytial virus (BRSV) and parainfluenza virus 3 (Pi3) - can be administered simultaneously,* from birth, thus ensuring the broadest early and rapid protection on the market against the three main viruses responsible for respiratory diseases.1,2
*One vaccine per nostril, do not mix
1RCP BOVILIS® Nasalgen®-C 2RCP BOVILIS® INtranasal RSP® Live
ELV- FR-BOV-250700002 – N°AP 2025/4718
- Where to find it
- Hall 4 - A46
